Cargando…

Corrigendum to: “Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial”

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526730/ https://www.ncbi.nlm.nih.gov/pubmed/32905598 http://dx.doi.org/10.1210/clinem/dgaa614

Ejemplares similares

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

SAT642 Effective Gh Replacement With Once-weekly Somapacitan In Children With Gh Deficiency: 2-year Results From Real4
por: Miller, Bradley Scott, et al.
Publicado: (2023)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

Correction to: “Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH”
Publicado: (2023)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial
por: Miller, Bradley, et al.
Publicado: (2022)

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
por: Miller, Bradley S, et al.
Publicado: (2022)

SAT-091 First Report of Disease-Specific Patient-Reported Outcomes from a Randomized Phase 2 Trial of Once-Weekly Somapacitan vs Daily GH in Children with GHD
por: Brod, Meryl, et al.
Publicado: (2020)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
por: Miller, Bradley S, et al.
Publicado: (2023)

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2023)

Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
por: Chatelain, Pierre, et al.
Publicado: (2023)

Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
por: Miller, Bradley S, et al.
Publicado: (2023)

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
por: Otsuka, Fumio, et al.
Publicado: (2020)

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial
por: Savendahl, Lars S, et al.
Publicado: (2020)

GH deficiency status combined with GH receptor polymorphism affects response to GH in children
por: Valsesia, Armand, et al.
Publicado: (2015)

SAT643 Patient Preference Questionnaire Response After Switching To Somapacitan After Taking Daily Gh: 2-year Results From REAL4
por: Blair, Joanne, et al.
Publicado: (2023)

RF26 | PMON335 Once-Weekly Somapacitan Versus Daily Growth Hormone in Children Born Small for Gestational Age: Results From a Randomized Phase 2 Trial
por: Juul, Anders, et al.
Publicado: (2022)

OR21-01 Pre-treatment Blood Transcriptome Predicts First-year Growth And IGF-I Response To Somapacitan Treatment In Children With GH Deficiency
por: Garner, Terence, et al.
Publicado: (2023)

Correction to: Functional analysis of GhCHS, GhANR and GhLAR in colored fiber formation of Gossypium hirsutum L
por: Gao, Jianfang, et al.
Publicado: (2020)

Is GH Replacement for Adult GH Deficiency Safe?
por: Melmed, Shlomo
Publicado: (2022)

Prospective Safety Surveillance of GH-Deficient Adults: Comparison of GH-Treated vs Untreated Patients
por: Hartman, Mark L., et al.
Publicado: (2013)

Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study
por: Gomez, Roy, et al.
Publicado: (2023)

Diagnosis of GH Deficiency Without GH Stimulation Tests
por: Ibba, Anastasia, et al.
Publicado: (2022)

SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3)
por: Savendahl, Lars, et al.
Publicado: (2019)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

GH deficiency and insensitivity in children and adults
por: Johannsson, Gudmundur, et al.
Publicado: (2021)

Thyroid function in children with growth hormone (GH) deficiency during the initial phase of GH replacement therapy - clinical implications
por: Smyczynska, Joanna, et al.
Publicado: (2010)

No Improvement of Adult Height in Non-growth Hormone (GH) Deficient Short Children with GH Treatment
por: Tanaka, Toshiaki, et al.
Publicado: (2006)

Metabolomics: a tool for the diagnosis of GH deficiency and for monitoring GH replacement?
por: Höybye, Charlotte, et al.
Publicado: (2014)

More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children
por: Ciresi, Alessandro, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials
por: Juul, Rasmus Vestergaard, et al.
Publicado: (2018)

Atypical Course of a Patient With AIP-Positive Acromegaly: From GH Excess to GH Deficiency and Back to GH Excess
por: García-de-la-Torre, Keren-Sandyn, et al.
Publicado: (2023)

Favorable Impacts of Growth Hormone (GH) Replacement Therapy on Atherogenic Risks in Japanese Children with GH Deficiency
por: Kohno, Hitoshi, et al.
Publicado: (2012)

Therapeutic Efficacy and Safety of GH in Japanese Children with Down Syndrome Short Stature Accompanied by GH Deficiency
por: Meguri, Kyoko, et al.
Publicado: (2013)

Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study
por: Hou, Ling, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s67vo0qe3sn9n5l0m7cib2q39i